Dilon Technologies

Executive Summary

Dilon Technologies is a private medical device company specializing in women's healthcare and biosurgery, with a focus on innovative solutions for breast cancer diagnosis and treatment. Founded in 2002 and headquartered in Newport News, Virginia, the company has established a global presence with products sold in over 76 countries. Its flagship product, MarginProbe, is a groundbreaking real-time margin assessment tool that helps surgeons ensure complete tumor removal during breast-conserving surgery, reducing the need for repeat procedures. The technology addresses a critical unmet need in oncology, improving patient outcomes and lowering healthcare costs. Dilon has a strong portfolio of medical devices and leverages over two decades of experience to expand into adjacent markets, including biosurgery. As a privately held company, Dilon operates with agility and focuses on clinical differentiation to drive adoption. With the growing emphasis on precision surgery and value-based care, Dilon's technology is well-positioned for market expansion and potential partnerships with larger healthcare organizations. However, the lack of publicly disclosed financials and competitive pressures from other intraoperative imaging technologies warrant cautious optimism.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance or CE marking for next-generation MarginProbe or biosurgery product60% success
• Q4 2026Strategic partnership or distribution agreement with a major medical device company50% success
• Q2 2026Publication of key clinical data supporting MarginProbe outcomes in peer-reviewed journals70% success